The lung cancer market is expected to experience significant growth in the coming years, driven by increasing investment in research and development. The global lung cancer market is expected to reach USD 36.4 billion by 2027, with a compound annual growth rate (CAGR) of 13.6% from 2020 to 2027.
The increasing incidence of lung cancer is one of the primary factors driving the growth of the market. The disease is the leading cause of cancer-related deaths worldwide, and its incidence is expected to increase due to factors such as smoking, pollution, and genetic predisposition.
In response to the growing burden of lung cancer, there has been a significant increase in investment in research and development of new treatments. This includes the development of targeted therapies, immunotherapies, and liquid biopsy techniques.
Targeted therapies are a form of cancer treatment that target specific molecular abnormalities in cancer cells, while leaving healthy cells intact. Immunotherapies use the patient’s immune system to fight cancer cells. Liquid biopsy is a non-invasive diagnostic technique that involves analyzing a patient’s blood for the presence of cancer cells.
Increasing investment in research and development is expected to lead to the development of more effective treatments for lung cancer. For example, several clinical trials are currently underway to evaluate the effectiveness of combination therapies, which involve the use of multiple treatments in combination to improve patient outcomes.
The Asia-Pacific region is expected to be the fastest-growing market for lung cancer treatment during the forecast period, driven by the increasing incidence of lung cancer in countries such as China and India.
In conclusion, increasing investment in research and development is expected to drive the growth of the lung cancer market in the coming years. The development of targeted therapies, immunotherapies, and liquid biopsy techniques is expected to lead to the development of more effective treatments for lung cancer. The Asia-Pacific region is expected to be a key market for lung cancer treatment during the forecast period, and companies operating in the market are expected to focus on expanding their presence in the region to capitalize on the growing demand for treatments.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Everest Market Insights journalist was involved in the writing and production of this article.